<DOC>
	<DOCNO>NCT03075735</DOCNO>
	<brief_summary>PROREPAIR prospective multicenter observational cohort study unselected patient metastatic Castration Resistant Prostate Cancer ( mCRPC ) unknown germline mutational status study entry candidate start 1st line treatment approve survival-prolonging agent . The study aim evaluate impact aberration DNA-repair gene , ( BRCA1 , BRCA2 , ATM PALB2 gene ) cause-specific survival diagnosis metastatic castration resistant status outcome .</brief_summary>
	<brief_title>Prospective Multicentre Cohort Study PROREPAIR-B ( mCRPC )</brief_title>
	<detailed_description>This non-interventional study eligible patient prospectively followed-up death end-of-study , whichever happen first . Patients enrol mCRPC diagnosis within 6 first month start first-line treatment approve survival-prolonging agent mCRPC . First subsequent treatment line choose accord patient treat physician preference dictate study . A whole blood sample germline DNA extraction well available archival prostate cancer tissue sample collect baseline . Optional plasma , serum whole blood sample collect baseline different time point along evolution disease . A sample collect within last 6 month life . Survival treatment outcomes include biochemical , radiological clinical progression standard approve agent abiraterone , enzalutamide , docetaxel , cabazitaxel radium-223 prospectively collect . Primary aim evaluate prevalence impact DNA repair germline mutation BRCA1 , BRCA2 , ATM PALB2 gene cause-specific survival mCRPC . Secondary aim include correlation additional germline alteration DNA-repair survival treatment outcomes ; analyse survival treatment outcome impact somatic alteration gene role germline somatic defect clonal evolution prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Provision sign informed consent . 2 . Patients must ≥18 year old . 3 . Histologically confirm prostate cancer 4. presence metastatic disease accord Bone , CT and/or MRIscan . 5 . Confirmed castration resistant prostate cancer define disease progression despite castrate level testosterone ( &lt; 0.5ng/mL ) either continuous rise serum prostatespecific antigen ( PSA ) level , progression preexist disease /or appearance new metastasis . Patients must maintain aLHRH underwent bilateral orchiectomy . 6 . Eligible patient due start start firstline treatment approve survivalprolonging therapy mCRPC within period 6 month study entry . 7 . ECOG performance status ≤21 . 8 . Unknown mutation carrier status study entry . 1 . Previous cancer diagnosis , except patient localize malignant tumour five year cancerfree diagnose skin cancer ( nonmelanoma type ) excise situ carcinoma . 2 . Any prior medical history accord judgement investigator might interfere subject´s grant informed consent safe execution procedure require study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Castration-Resistant Prostate Cancer</keyword>
	<keyword>DNA-repair</keyword>
	<keyword>BRCA1</keyword>
	<keyword>BRCA2</keyword>
	<keyword>ATM</keyword>
	<keyword>PALB2</keyword>
</DOC>